HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.109.069492v1 51/3/427    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by He, J. Articles by Liu, B. PubMed PubMed Citation Articles by He, J. Articles by Liu, B.

Targeting Prostate Cancer Cells In Vivo Using a Rapidly Internalizing Novel Human Single-Chain Antibody Fragment

¹ Department of Radiology and Biomedical Imaging, Center for Molecular and Functional Imaging, University of California at San Francisco, San Francisco, California; ² Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California; and ³ Department of Anesthesia, University of California at San Francisco, San Francisco, California

Correspondence: For correspondence or reprints contact either of the following: Jiang He, Department of Radiology and Biomedical Imaging, Center for Molecular and Functional Imaging, University of California at San Francisco, 185 Berry St., Suite 350, San Francisco, CA 94143. E-mail: Jiang.He{at}radiology.ucsf.edu

Correspondence: Bin Liu, Department of Anesthesia, University of California at San Francisco, 1001 Potrero Ave., 3C38, San Francisco, CA 94110. E-mail: liub{at}anesthesia.ucsf.edu

Human antibodies targeting prostate cancer cell surface epitopes may be useful for imaging and therapy. The objective of this study was to evaluate the tumor targeting of an internalizing human antibody fragment, a small-size platform, to provide high contrast in a mouse model of human prostate carcinoma. Methods: A prostate tumor–targeting single-chain antibody fragment (scFv), UA20, along with a nonbinding control scFv, N3M2, were labeled with ^99mTc and evaluated for binding and rapid internalization into human prostate tumor cells in vitro and tumor homing in vivo using xenograft models. For the in vitro studies, the labeled UA20 scFv was incubated at 37°C for 1 h with metastatic prostate cancer cells (DU145) to assess the total cellular uptake versus intracellular uptake. For the animal studies, labeled UA20 and N3M2 scFvs were administered to athymic mice implanted subcutaneously with DU145 cells. Mice were imaged with small-animal SPECT/CT with concomitant biodistribution at 1 and 3 h after injection. Results: The UA20 scFv was labeled in 55%–65% yield and remained stable in phosphate buffer within 24 h. The labeled UA20 scFv was taken up specifically by prostate tumor cells. Internalization was rapid, because incubation at 37°C for less than 1 h resulted in 93% internalization of total cell-associated scFvs. In animal studies, SPECT/CT showed significant tumor uptake as early as 1 h after injection. At 3 h after injection, tumor uptake was 4.4 percentage injected dose per gram (%ID/g), significantly greater than all organs or tissues studied (liver, 2.7 %ID/g; other organs or tissues, <1 %ID/g), except the kidneys (81.4 %ID/g), giving tumor-to-blood and tumor-to-muscle ratios of 12:1 and 70:1, respectively. In contrast, the control antibody exhibited a tumor uptake of only 0.26 %ID/g, similar to that of muscle and fat. Tumor-specific targeting was evidenced by reduced tumor uptake of nearly 70% on administration of a 10-fold excess of unlabeled UA20 scFv. Kidney uptake was nonspecific, consistent with the route of excretion by scFvs. Conclusion: The UA20 scFv showed rapid and specific internalization in prostate tumor cells in vitro and accumulation in prostate tumor xenografts in vivo, demonstrating the potential for future development for prostate cancer imaging and targeted therapy.

Key Words: molecular imaging • prostate cancer • antibody fragment

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2010 51: 11A-12A. [Full Text]  

This article has been cited by other articles:

				X. Zhu, S. Bidlingmaier, R. Hashizume, C. D. James, M. S. Berger, and B. Liu Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells Mol. Cancer Ther., July 1, 2010; 9(7): 2131 - 2141. [Abstract] [Full Text] [PDF]